FIRST COAST SERVICE OPTIONS
MAC - PART A/B
LOCAL COVERAGE DETERMINATION

LCD Database ID Number
L33669

Contractor Name
First Coast Service Options, Inc.

Contractor Number
09101 - Florida
09201 – PR/USVI
09102 – Florida
09202 – Puerto Rico
09302 – Virgin Islands

Contractor Type
MAC – Part A and B

LCD Title
Electrocardiography

AMA CPT Copyright Statement

CPT only copyright 2002-2017 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Applicable FARs/DFARs apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. The Code on Dental Procedures and Nomenclature (Code) is published in Current Dental Terminology (CDT). Copyright (c) American Dental Association. All rights reserved. CDT and CDT-2010 are trademarks of the American Dental Association.

CMS National Coverage Policy

Language quoted from CMS National Coverage Determinations (NCDs) and coverage provisions in interpretive manuals are italicized throughout the Local Coverage Determination (LCD). NCDs and coverage provisions in interpretive manuals are not subject to the LCD Review Process (42 CFR 405.860[b] and 42 CFR 426 [Subpart D]). In addition, an administrative law judge may not review an NCD. See §1869(f)(1)(A)(i) of the Social Security Act.

Unless otherwise specified, italicized text represents quotation from one or more of the following CMS sources:

CMS Manual System, Pub. 100-02, Medicare Benefit Policy Manual, Chapter 6, Section 20.3
CMS Manual System, Pub. 100-03, Medicare National Coverage Determinations, Chapter 1, Section 20.15
CMS Manual System, Pub. 100-08, Medicare Program Integrity Manual, Chapter 13, Section 13.1.3
Primary Geographic Jurisdiction
Florida
Puerto Rico/Virgin Islands

Oversight Region
Region I

Original Determination Effective Date
10/01/2015

Original Determination Ending Date
N/A

Revision Effective Date
10/01/2017

Revision Ending Date
09/30/2017

Indications and Limitations of Coverage and/or Medical Necessity

An electrocardiogram (EKG) is a graphic representation of electrical activity within the heart. Electrodes placed on the body in predetermined locations sense this electrical activity, which is then recorded by various means for review and interpretation. EKG recordings are used to diagnose a wide range of heart disease and other conditions that manifest themselves by abnormal cardiac electrical activity.

EKG services are covered diagnostic tests when there are documented signs and symptoms or other clinical indications for providing the service. Coverage includes the review and interpretation of EKG’s only by a physician. There is no coverage for EKG services when rendered as a screening test or as part of a routine examination unless performed as part of the one-time, “Welcome to Medicare” preventive physical examination under section 611 of the Medicare Prescription Drug, Improvement and Modernization Act of 2003.

Electrocardiograms are indicated for diagnosis and patient management purposes involving symptoms of the heart, pericardium, thoracic cavity, and systemic diseases which produce cardiac abnormalities.

An EKG will be considered medically necessary in any of the following circumstances:

1. Initial diagnostic workup for a patient that presents with complaints of symptoms such as chest pain, palpitations, dyspnea, dizziness, syncope, etc. which may suggest a cardiac origin.
2. Evaluation of a patient on a cardiac medication for a cardiac arrhythmia or other cardiac condition which affects the electrical conduction system of the heart (e.g., inotropics such as digoxin; antiarrhythmics such as Tambocor, Procainamide, or Quinidine; and antianginals such as Cardizem, Isordil, Corgard, Procardia, Inderal and Verapamil). The EKG is necessary to evaluate the effect of the cardiac medication on the patient’s cardiac rhythm and/or conduction system.
3. Evaluation of a patient with a pacemaker with or without clinical findings (history or physical examination) that suggest possible pacemaker malfunction.
4. Evaluation of a patient who has a significant cardiac arrhythmia or conduction disorder in which an EKG is necessary as part of the evaluation and management of the patient. These disorders may include, but are not limited to, the following: Complete Heart Block, Second Degree AV Block, Left Bundle Branch Block, Right Bundle Branch Block, Paroxysmal VT, Atrial
Electrocardiography.2 A/B

Fib/Flutter, Ventricular Fib/Flutter, Cardiac Arrest, Frequent PVCs, Frequent PACs, Wandering Atrial Pacemaker, and any other unspecified cardiac arrhythmia.

5. Evaluation of a patient with known Coronary Artery Disease (CAD) and/or heart muscle disease that presents with symptoms such as increasing shortness of breath (SOB), palpitations, angina, etc.

6. Evaluation of a patient’s response to a newly established therapy for angina, palpitations, arrhythmias, SOB or other cardiopulmonary disease process.

7. Evaluation of patients after coronary artery revascularization by Coronary Artery Bypass Grafting (CABGs), Percutaneous Transluminal Coronary Angiography (PTCA), thrombolytic therapy (e.g., TPA, Streptokinase, Urokinase), and/or stent placement.

8. Evaluation of patients presenting with symptoms of a Myocardial Infarction (MI).

9. Evaluation of other symptomatology which may indicate a cardiac origin especially in those patients who have a history of an MI, CABG surgery or PTCA or patients who are being treated medically after a positive stress test or cardiac catheterization.

10. Pre-operative Evaluation of the patient when:
    - undergoing cardiac surgery such as CABGs, automatic implantable cardiac defibrillator, or pacemaker, or
    - the patient has a medical condition associated with a significant risk of serious cardiac arrhythmia and/or myocardial ischemia such as Diabetes, history of MI, angina pectoris, aneurysm of heart wall, chronic ischemic heart disease, pericarditis, valvular disease or cardiomyopathy to name a few.

11. Evaluation of a patient’s response to the administration of an agent known to result in cardiac or EKG abnormalities (for patients with suspected, or at increased risk of developing, cardiovascular disease or dysfunction). Examples of these agents are antineoplastic drugs, lithium, tranquilizers, anticonvulsants, and antidepressant agents.

12. When performed as a baseline evaluation prior to the initiation of an agent known to result in cardiac or EKG abnormalities. An example of such an agent is verapamil.

Type of Bill Code

Outpatient Hospital - 12x, 13x, 14x
Skilled Nursing Facility - 21x, 22x, 23x
Comprehensive Outpatient Rehabilitation Facility - 75x
Critical Access Hospital – 85x

Revenue Codes

730 Electrocardiogram, General Classification

CPT/HCPCS Codes

93000 Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report

93005 tracing only, without interpretation and report

93010 interpretation and report only

ICD-10 Codes that Support Medical Necessity

A02.1 Salmonella sepsis
A22.7 Anthrax sepsis
A18.84 Tuberculosis of heart
A26.7 Erysipelothrix sepsis
A32.7 Listerial sepsis
A40.0-A40.9 Streptococcal sepsis
A41.01-A41.9 Other sepsis
A42.7 Actinomycotic sepsis
A54.86 Gonococcal sepsis
A74.81 Chlamydial peritonitis
A74.9 Chlamydial infection, unspecified
Electrocardiography

B33.3-B34.8 Certain infectious and parasitic diseases
B37.7 Candidal sepsis
B97.0-B97.89 Viral agents as the cause of diseases classified elsewhere
E00.0-E03.4 Endocrine, nutritional and metabolic diseases
E03.8-E07.1 Endocrine, nutritional and metabolic diseases
E07.89-E07.9 Other disorders of thyroid
E08.51-E08.52 Diabetes mellitus due to underlying condition with circulatory complications
E09.51-E09.52 Drug or chemical induced diabetes mellitus with circulatory complications
E10.10-E13.9 Endocrine, nutritional and metabolic diseases
E35 Disorders of endocrine glands in diseases classified elsewhere
E40.0-E40.9 Cystic fibrosis
E51.1-E58.89 Neuropathic heredofamilial amyloidosis - Other amyloidosis
E58.9 Amyloidosis, unspecified
E86.0-E86.9 Volume depletion
E87.0 Hypersmolality and hypernatremia
E87.1 Hypo-osmolality and hyponatremia
E87.2 Acidosis
E87.3 Alkalosis
E87.4 Mixed disorder of acid-base balance
E87.5 Hyperkalemia
E87.6 Hypokalemia
E87.70 Fluid overload, unspecified
E87.79 Other fluid overload
E87.8 Other disorders of electrolyte and fluid balance, not elsewhere classified
E89.0 Postprocedural hypothyroidism
G45.9 Transient cerebral ischemic attack, unspecified
G90.01 Carotid sinus syncope
G90.09 Other idiopathic peripheral autonomic neuropathy
G90.2 Horner's syndrome
G90.8 Other disorders of autonomic nervous system
G90.9 Disorder of the autonomic nervous system, unspecified
G93.3 Postviral fatigue syndrome
I00.0-I02.9 Acute rheumatic fever
I05.0-I09.9 Chronic rheumatic heart diseases
I10-I14.9 Hypertensive diseases
I16.0-I16.9 Hypertensive crisis
I20.0-I25.9 Unstable angina-Chronic ischemic heart disease, unspecified
I26.01-I28.9 Pulmonary heart disease and diseases of pulmonary circulation
I30.0-I52 Other forms of heart disease
I67.0 Dissection of cerebral arteries, nonruptured
I67.841 Reversible cerebrovascular vasoconstriction syndrome
I67.848 Other cerebrovascular vasospasm and vasoconstriction
I67.89 Other cerebrovascular disease
I70.0-I75.89 Diseases of arteries, arterioles and capillaries
I77.0-I79.8 Diseases of arteries, arterioles and capillaries
I97.0-I97.191 Intraoperative and postprocedural complications and disorders of circulatory system, not
I97.710-I97.791 Intraoperative cardiac functional disturbances
I97.88-I97.89 Other intraoperative and postprocedural complications and disorders of the
J20.3-J20.7 Acute bronchitis
J95.4-J95.5 Intraoperative and postprocedural complications and disorders of respiratory system, not elsewhere classified
J95.859-J95.89 Other intraoperative and postprocedural complications and disorders of respiratory system, not elsewhere classified
M1A.10X0-M1A.19X1  Lead-induced chronic gout
M05.00-M06.9  Diseases of the musculoskeletal system and connective tissue
M08.00-M08.09  Unspecified juvenile rheumatoid arthritis
M08.20-M08.99  Juvenile arthritis
M12.00-M12.09  Chronic postrheumatic arthropathy [Jaccoud]
M30.0-M35.1  Systemic connective tissue disorders
M35.5  Multifocal fibrosclerosis
M35.8-M36.0  Systemic connective tissue disorders
M36.8  Systemic disorders of connective tissue in other diseases classified elsewhere
M79.601-M79.676  Pain in limb, hand, foot, fingers and toes
N26.2  Page kidney
O74.2  Cardiac complications of anesthesia during labor and delivery
O89.1  Cardiac complications of anesthesia during the puerperium

P29.30 – P29.38  Pulmonary hypertension of newborn - Other persistent fetal circulation
Q20.0-Q20.8  Congenital malformations of cardiac chambers and connections
Q20.9  Congenital malformation of cardiac chambers and connections, unspecified
Q21.0-Q21.9  Congenital malformations of cardiac septa
Q22.0-Q24.9  Congenital malformations of the circulatory system
Q25.0-Q28.9  Congenital malformations of the circulatory system
R00.0  Tachycardia, unspecified
R00.1  Bradycardia, unspecified
R00.2  Palpitations
R00.8-R00.9  Abnormalities of heart beat
R01.0-R01.2  Cardiac murmurs and other cardiac sounds
R06.00-R06.09  Dyspnea
R06.2-R06.4  Abnormalities of breathing
R06.81-R06.9  Abnormalities of breathing
R07.1-R07.9  Pain in throat and chest
R09.01-R09.02  Asphyxia and hypoxemia
R09.2  Respiratory arrest
R10.11  Right upper quadrant pain
R10.12  Left upper quadrant pain
R10.13  Epigastric pain
R20.0-R20.9  Disturbances of skin sensation
R22.2  Localized swelling, mass and lump, trunk
R23.1-R23.2  Other skin changes
R40.4  Transient alteration of awareness
R42  Dizziness and giddiness
R53.0-R53.1  Malaise and fatigue
R53.81  Other malaise
R53.83  Other fatigue
R55  Syncope and collapse
R56.00-R56.9  Convulsions, not elsewhere classified
R57.0-R57.9  Shock, not elsewhere classified
R65.10-R65.21  Symptoms and signs specifically associated with systemic inflammation and infection
R94.30-R94.39  Abnormal results of cardiovascular function studies
S26.00XA-S26.99XS  Injury of heart with hemopericardium,
S27.0XXA-S27.399S  Injury of other and unspecified intrathoracic organs
S29.001A-S29.099S  Unspecified injury of muscle and tendon of thorax
S29.091A-S29.099S  Other injury of muscle and tendon of thorax
S29.8XXA-S29.8XXS  Other specified injuries of thorax, initial encounter
S29.9XXA-S29.9XXS  Unspecified injury of thorax, initial encounter
S39.001A-S39.003S  Unspecified injury of muscle, fascia and tendon of abdomen, lower back and pelvis
S39.091A-S39.093S  Other injury of muscle, fascia and tendon of abdomen, lower back and pelvis
S39.81XA-S39.94XS  Other specified and unspecified injuries of abdomen, lower back, pelvis and external genitals
Electrocardiography.2 A/B

T36.0X5A-T36.0X5S  Adverse effect of penicillins, initial encounter
T36.1X5A-T36.1X5S  Adverse effect of cephalosporins and other beta-lactam antibiotics, initial encounter
T36.2X5A-T36.2X5S  Adverse effect of chloramphenicol group, initial encounter
T36.3X5A-T36.3X5S  Adverse effect of macrolides, initial encounter
T36.4X5A-T36.4X5S  Adverse effect of tetracyclines, initial encounter
T36.5X5A-T36.5X5S  Adverse effect of aminoglycosides, initial encounter
T36.6X5A-T36.6X5S  Adverse effect of rifampicins, initial encounter
T36.7X5A-T36.7X5S  Adverse effect of antifungal antibiotics, systemically used, initial encounter
T36.8X5A-T36.8X5S  Adverse effect of other systemic antibiotics, initial encounter
T36.95XA-T36.95XS  Adverse effect of unspecified systemic antibiotic, initial encounter
T37.0X5A-T37.0X5S  Adverse effect of sulfonamides, initial encounter
T37.1X5A-T37.1X5S  Adverse effect of antimycobacterial drugs, initial encounter
T37.2X5A-T37.2X5S  Adverse effect of antimalarials and drugs acting on other blood protozoa, initial encounter
T37.3X5A-T37.3X5S  Adverse effect of other antiprotozoal drugs, initial encounter
T37.4X5A-T37.4X5S  Adverse effect of anthelmintics, initial encounter
T37.5X5A-T37.5X5S  Adverse effect of antiviral drugs, initial encounter
T37.8X5A-T37.8X5S  Adverse effect of other specified systemic anti-infectives and antiparasitics, initial encounter
T37.95XA-T37.95XS  Adverse effect of unspecified systemic anti-infective and antiparasitic, initial encounter
T38.0X5A-T38.0X5S  Adverse effect of glucocorticoids and synthetic analogues, initial encounter
T38.1X5A-T38.1X5S  Adverse effect of thyroid hormones and substitutes, initial encounter
T38.2X5A-T38.2X5S  Adverse effect of antithyroid drugs, initial encounter
T38.3X5A-T38.3X5S  Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, initial encounter
T38.4X5A-T38.4X5S  Adverse effect of oral contraceptives, initial encounter
T38.5X5A-T38.5X5S  Adverse effect of other estrogens and progestogens, initial encounter
T38.6X5A-T38.6X5S  Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, initial encounter
T38.7X5A-T38.7X5S  Adverse effect of androgens and anabolic congeners, initial encounter
T38.805A-T38.805S  Adverse effect of unspecified hormones and synthetic substitutes, initial encounter
T38.815A-T38.815S  Adverse effect of anterior pituitary [adenohypophyseal] hormones, initial encounter
T38.895A-T38.895S  Adverse effect of other hormones and synthetic substitutes, initial encounter
T38.905A-T38.905S  Adverse effect of unspecified hormone antagonists, initial encounter
T38.99XA-T38.99XS  Initial effect of other hormone antagonists, initial encounter
T39.015A- T39.015S Adverse effect of aspirin, initial encounter
T39.095A-S  Adverse effect of salicylates, initial encounter
T39.1X5A-S  Adverse effect of 4-Aminophenol derivatives, initial encounter
T39.2X5A-S  Adverse effect of pyrazolone derivatives, initial encounter
T39.315A- S  Adverse effect of propionic acid derivatives, initial encounter
T39.395A- S  Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], initial encounter
T39.4X5A- S  Adverse effect of antirheumatics, not elsewhere classified, initial encounter
T39.8X5A- S  Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, initial encounter
T39.95XA-S  Adverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic, initial encounter
T40.0X5A-S  Adverse effect of opium, initial encounter
T40.2X5A-S  Adverse effect of other opioids, initial encounter
T40.3X5A-S  Adverse effect of methadone, initial encounter
T40.4X5A-S  Adverse effect of other synthetic narcotics, initial encounter
*T40.5X5A-S  Adverse effect of cocaine, initial encounter
T40.605A-S  Adverse effect of unspecified narcotics, initial encounter
T40.695A-S  Adverse effect of other narcotics, initial encounter
*T40.7X5A-S  Adverse effect of cannabis (derivatives), initial encounter
*T40.905A-S  Adverse effect of unspecified psychodysleptics [hallucinogens], initial encounter
*T40.995A-S  Adverse effect of other psychodysleptics [hallucinogens], initial encounter
Electrocardiography.2 A/B

T41.0X5A-S  Adverse effect of inhaled anesthetics, initial encounter
T41.1X5A-S  Adverse effect of intravenous anesthetics, initial encounter
T41.205A-S  Adverse effect of unspecified general anesthetics, initial encounter
T41.295A-S  Adverse effect of other general anesthetics, initial encounter
T41.3X5A-S  Adverse effect of local anesthetics, initial encounter
T41.45XA-S  Adverse effect of unspecified anesthetic, initial encounter
T41.5X5A-S  Adverse effect of therapeutic gases, initial encounter
*T42.0X5A-S Adverse effect of hydantoin derivatives, initial encounter
*T42.1X5A-S Adverse effect of iminostilbenes, initial encounter
*T42.2X5A-S Adverse effect of succinimides and oxazolidinediones, initial encounter
T42.3X5A-S  Adverse effect of barbiturates, initial encounter
*T42.4X5A-S Adverse effect of benzodiazepines, initial encounter
*T42.5X5A-S Adverse effect of mixed antiepileptics, initial encounter
*T42.6X5A-S Adverse effect of other antiepileptic and sedative-hypnotic drugs, initial encounter
*T42.75XA-S Adverse effect of unspecified antiepileptic and sedative-hypnotic drugs, initial encounter
T42.8X5A-S  Adverse effect of antiparkinsonism drugs and other central muscle-tone depressants, initial encounter
*T43.015A-S Adverse effect of tricyclic antidepressants, initial encounter
*T43.025A-S Adverse effect of tetracyclic antidepressants, initial encounter
*T43.1X5A-S Adverse effect of monoamine-oxidase-inhibitor antidepressants, initial encounter
*T43.205A-S  Adverse effect of unspecified antidepressants, initial encounter
*T43.215A-S  Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, initial encounter
*T43.225A-S  Adverse effect of selective serotonin reuptake inhibitors, initial encounter
*T43.295A-S  Adverse effect of other antidepressants, initial encounter
*T43.3X5A-S  Adverse effect of phenothiazine antipsychotics and neuroleptics, initial encounter
*T43.4X5A-S  Adverse effect of butyrophenone and thiothixene neuroleptics, initial encounter
*T43.505A-S  Adverse effect of unspecified antipsychotics and neuroleptics, initial encounter
*T43.595A-S  Adverse effect of other antipsychotics and neuroleptics, initial encounter
*T43.605A-S  Adverse effect of unspecified psychostimulants, initial encounter
*T43.625A-S  Adverse effect of amphetamines, initial encounter
*T43.635A-S  Adverse effect of methylphenidate, initial encounter
*T43.695A-S  Adverse effect of other psychostimulants, initial encounter
*T43.8X5A-S  Adverse effect of other psychotropic drugs, initial encounter
*T43.9X5A-S  Adverse effect of unspecified psychotropic drug, initial encounter
T44.0X5A-S  Adverse effect of anticholinesterase agents, initial encounter
T44.1X5A-S  Adverse effect of other parasympathomimetics [cholinergics], initial encounter
T44.21A-T44.2X5S Poisoning by ganglionic blocking drugs, accidental (unintentional), initial encounter
T44.3X5A-S  Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmylics, initial encounter
T44.4X5A-S  Adverse effect of predominantly alpha-adrenoreceptor agonists, initial encounter
T44.5X5A-S  Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter
T44.6X5A-S  Adverse effect of alpha-adrenoreceptor antagonists, initial encounter
T44.7X5A-S  Adverse effect of beta-adrenoreceptor antagonists, initial encounter
T44.8X5A-S  Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, initial encounter
T44.905A-S  Adverse effect of unspecified drugs primarily affecting the autonomic nervous system, initial encounter
T44.995A-S  Adverse effect of other drug primarily affecting the autonomic nervous system, initial encounter
T45.0X5A-S  Adverse effect of antiallergic and antiemetic drugs, initial encounter
*T45.1X5A-S Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter
T45.2X5A-S  Adverse effect of vitamins, initial encounter
T45.3X5A-S  Adverse effect of enzymes, initial encounter
T45.4X5A-S  Adverse effect of iron and its compounds, initial encounter
Electrocardiography.2 A/B

T45.515A-S Adverse effect of anticoagulants, initial encounter
T45.525A-S Adverse effect of antithrombotic drugs, initial encounter
T45.605A-S Adverse effect of unspecified fibrinolysis-affecting drugs, initial encounter
T45.615A-S Adverse effect of thrombolytic drugs, initial encounter
T45.625A-S Adverse effect of hemostatic drug, initial encounter
T45.695A-S Adverse effect of other fibrinolysis-affecting drugs, initial encounter
T45.7X5A-S Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, initial encounter
T45.8X5A-S Adverse effect of other primarily systemic and hematological agents, initial encounter
T45.95XA-S Adverse effect of unspecified primarily systemic and hematological agent, initial encounter
T46.0X1A-T46.0X5S Poisoning by cardiac-stimulant glycosides and drugs of similar action, accidental (unintentional), initial encounter
T46.1X1A-T46.1X5S Poisoning by calcium-channel blockers, accidental (unintentional), initial encounter
T46.2X1A-T46.2X5S Poisoning by other antidysrhythmic drugs, accidental (unintentional), initial encounter
T46.3X1A-T46.3X5S Poisoning by coronary vasodilators, accidental (unintentional), initial encounter
T46.4X1A-T46.4X5S Poisoning by angiotensin-converting-enzyme inhibitors, accidental (unintentional), initial encounter
T46.5X1A-T46.5X5S Poisoning by other antihypertensive drugs, accidental (unintentional), initial encounter
T46.6X1A-T46.6X5S Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, accidental (unintentional), initial encounter
T46.7X1A-T46.7X5S Poisoning by peripheral vasodilators, accidental (unintentional), initial encounter
T46.8X1A-T46.8X5S Poisoning by antivascular drugs, including sclerosing agents, accidental (unintentional), initial encounter
T46.901A-T46.905S Poisoning by unspecified agents primarily affecting the cardiovascular system, accidental (unintentional), initial encounter
T46.991A-T46.995S Poisoning by other agents primarily affecting the cardiovascular system, accidental (unintentional), initial encounter
T47.0X5A-S Adverse effect of histamine H2-receptor blockers, initial encounter
T47.1X5A-S Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter
T47.2X5A-S Adverse effect of stimulant laxatives, initial encounter
T47.3X5A-S Adverse effect of saline and osmotic laxatives, initial encounter
T47.4X5A-S Adverse effect of other laxatives, initial encounter
T47.5X5A-S Adverse effect of digestants, initial encounter
T47.6X5A-S Adverse effect of antidiarrheal drugs, initial encounter
T47.7X5A-S Adverse effect of emetics, initial encounter
T47.8X5A-S Adverse effect of other agents primarily affecting gastrointestinal system, initial encounter
T47.9X5A-S Adverse effect of unspecified agents primarily affecting the gastrointestinal system, initial encounter
T48.0X5A-S Adverse effect of oxytocic drugs, initial encounter
T48.1X5A-S Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], initial encounter
T48.205A-S Adverse effect of unspecified drugs acting on muscles, initial encounter
T48.295A-S Adverse effect of other drugs acting on muscles, initial encounter
T48.3X5A-S Adverse effect of antitussives, initial encounter
T48.4X5A-S Adverse effect of expectorants, initial encounter
T48.5X5A-S Adverse effect of other anti-common-cold drugs, initial encounter
T48.6X5A-S Adverse effect of antiasthmatics, initial encounter
T48.905A-S Adverse effect of unspecified agents primarily acting on the respiratory system, initial encounter
T48.995A-S Adverse effect of other agents primarily acting on the respiratory system, initial encounter
T49.0X5A-S Adverse effect of local antifungal, anti-infective and anti-inflammatory drugs, initial encounter
T49.1X5A-S Adverse effect of antipruritics, initial encounter
T49.2X5A-S  Adverse effect of local astringents and local detergents, initial encounter
T49.3X5A-S  Adverse effect of emollients, demulcets and protectants, initial encounter
T49.4X5A-S  Adverse effect of keratolytics, keratoplastics, and other hair treatment drugs and preparations, initial encounter
T49.5X5A-S  Adverse effect of ophthalmological drugs and preparations, initial encounter
T49.6X5A-S  Adverse effect of otolaryngological drugs and preparations, initial encounter
T49.7X5A-S  Adverse effect of dental drugs, topically applied, initial encounter
T49.8X5A-S  Adverse effect of other topical agents, initial encounter
T49.95XA-S  Adverse effect of unspecified topical agent, initial encounter
T50.0X5A-S  Adverse effect of mineralocorticoids and their antagonists, initial encounter
T50.1X5A-S  Adverse effect of loop [high-ceiling] diuretics, initial encounter
T50.2X5A-S  Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, initial encounter
T50.3X5A-S  Adverse effect of electrolytic, caloric and water-balance agents, initial encounter
T50.4X5A-S  Adverse effect of drugs affecting uric acid metabolism, initial encounter
T50.5X5A-S  Adverse effect of appetite depressants, initial encounter
T50.6X5A-S  Adverse effect of antidotes and chelating agents, initial encounter
T50.7X5A-S  Adverse effect of analeptics and opioid receptor antagonists, initial encounter
T50.8X5A-S  Adverse effect of diagnostic agents, initial encounter
T50.905A-S  Adverse effect of unspecified drugs, medicaments and biological substances, initial encounter
T50.995A-S  Adverse effect of other drugs, medicaments and biological substances, initial encounter
T50.A15A-S  Adverse effect of pertussis vaccine, including combinations with a pertussis component, initial encounter
T50.A25A-S  Adverse effect of mixed bacterial vaccines without a pertussis component, initial encounter
T50.A95A-S  Adverse effect of other bacterial vaccines, initial encounter
T50.B15A-S  Adverse effect of smallpox vaccines, initial encounter
T50.B95A-S  Adverse effect of other viral vaccines, initial encounter
T50.Z15A-S  Adverse effect of immunoglobulin, initial encounter
T50.Z95A-S  Adverse effect of other vaccines and biological substances, initial encounter
T51.0X1A-T65.94XS  Toxic effect of substances chiefly nonmedicinal as to source
T78.00XA-T78.8XXS  Adverse effects, not elsewhere classified
T81.718A-S  Complication of other artery following a procedure, not elsewhere classified, initial encounter
T81.719A-S  Complication of unspecified artery following a procedure, not elsewhere classified, initial encounter
T81.72XA-S  Complication of vein following a procedure, not elsewhere classified, initial encounter
T82.01XA-T82.228S  Complications of cardiac and vascular prosthetic devices, implants and grafts
T82.512A-S  Breakdown (mechanical) of artificial heart, initial encounter
T82.514A-S  Breakdown (mechanical) of infusion catheter, initial encounter
T82.518A-S  Breakdown (mechanical) of other cardiac and vascular devices and implants, initial encounter
T82.519A-S  Breakdown (mechanical) of unspecified cardiac and vascular devices and implants, initial encounter
T82.522A-S  Displacement of artificial heart, initial encounter
T82.524A-S  Displacement of infusion catheter, initial encounter
T82.528A-S  Displacement of other cardiac and vascular devices and implants, initial encounter
T82.529A-S  Displacement of unspecified cardiac and vascular devices and implants, initial encounter
T82.532A-S  Leakage of artificial heart, initial encounter
T82.534A-S  Leakage of infusion catheter, initial encounter
T82.538A-S  Leakage of other cardiac and vascular devices and implants, initial encounter
T82.539A-S  Leakage of unspecified cardiac and vascular devices and implants, initial encounter
**Electrocardiography.2 A/B**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>T82.592A-S</td>
<td>Other mechanical complication of artificial heart, initial encounter</td>
</tr>
<tr>
<td>T82.594A-S</td>
<td>Other mechanical complication of infusion catheter, initial encounter</td>
</tr>
<tr>
<td>T82.598A-S</td>
<td>Other mechanical complication of other cardiac and vascular devices and implants, initial encounter</td>
</tr>
<tr>
<td>T82.599A-S</td>
<td>Other mechanical complication of unspecified cardiac and vascular devices and implants, initial encounter</td>
</tr>
<tr>
<td>T86.00-T86.819</td>
<td>Complications of transplanted organs and tissue</td>
</tr>
<tr>
<td>T86.830-T86.839</td>
<td>Complications of bone graft</td>
</tr>
<tr>
<td>T86.850-T86.99</td>
<td>Complications of transplanted organs and tissue</td>
</tr>
<tr>
<td>T88.2XXA-S</td>
<td>Shock due to anesthesia, initial encounter</td>
</tr>
<tr>
<td>T88.3XXA-S</td>
<td>Malignant hyperthermia due to anesthesia, initial encounter</td>
</tr>
<tr>
<td>T88.51XA-S</td>
<td>Hypothermia following anesthesia, initial encounter</td>
</tr>
<tr>
<td>T88.52XA-S</td>
<td>Failed moderate sedation during procedure, initial encounter</td>
</tr>
<tr>
<td>T88.53XA – T88.53XS</td>
<td>Unintended awareness under general anesthesia during procedure, initial encounter - Unintended awareness under general anesthesia during procedure, sequela</td>
</tr>
<tr>
<td>T88.59XA-S</td>
<td>Other complications of anesthesia, initial encounter</td>
</tr>
<tr>
<td>T88.6XXA-S</td>
<td>Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered, initial encounter</td>
</tr>
<tr>
<td>Z01.810</td>
<td>Encounter for preprocedural cardiovascular examination</td>
</tr>
<tr>
<td>Z51.81</td>
<td>Encounter for therapeutic drug level monitoring</td>
</tr>
<tr>
<td>*Z79.3</td>
<td>Long term (current) use of hormonal contraceptives</td>
</tr>
<tr>
<td>*Z79.891</td>
<td>Long term (current) use of opiate analgesic</td>
</tr>
<tr>
<td>*Z79.899</td>
<td>Other long term (current) drug therapy</td>
</tr>
<tr>
<td>*Z95.0</td>
<td>Presence of cardiac pacemaker</td>
</tr>
<tr>
<td>*Z95.1</td>
<td>Presence of aortocoronary bypass graft</td>
</tr>
<tr>
<td>*Z95.5</td>
<td>Presence of coronary angioplasty implant and graft</td>
</tr>
<tr>
<td>*Z95.810</td>
<td>Presence of automatic (implantable) cardiac defibrillator</td>
</tr>
<tr>
<td>*Z95.818</td>
<td>Presence of other cardiac implants and grafts</td>
</tr>
<tr>
<td>*Z98.61</td>
<td>Coronary angioplasty status</td>
</tr>
</tbody>
</table>

*Refer to the ICD-10-CM book to determine if additional ICD-10-CM code(s) are needed to be billed for diagnosis codes T40.5X5A-T40.5X5S, T40.7X5A-T40.7X5S, T40.905A-T40.905S, T40.995A-T40.995S, T42.0X5A-T42.0X5S, T42.1X5A-T42.1X5S, T42.2X5A-T42.2X5S, T42.4X5A-T42.4X5S, T42.5X5A-T42.5X5S, T42.6X5A-T42.6X5S, T42.75XA-T42.75XS, T43.015A-T43.015S, T43.025A-T43.025S, T43.1X5A-T43.1X5S, T43.205A-T43.205S, T43.215A-T43.215S, T43.225A-T43.225S, T43.295A-T43.295S, T43.3X5A-T43.3X5S, T43.4X5A-T43.4X5S, T43.505A-T43.505S, T43.595A-T43.595S, T43.605A-T43.605S, T43.615A-T43.615S, T43.625A-T43.625S, T43.635A-T43.635S, T43.695A-T43.695S, T43.8X5A-T43.8X5S, T43.95XA-T43.95XS, Z79.3, Z79.891, Z95.0, Z95.1, Z95.5, Z95.810, Z95.818 and Z98.61.

**Diagnoses that Support Medical Necessity**

N/A

**ICD-10 Codes that DO NOT Support Medical Necessity**

N/A

**Diagnoses that DO NOT Support Medical Necessity**

N/A

**Associated Information**

**Documentation Requirements**
In order to be covered and reimbursed, a service must meet several requirements. It must fall within a defined benefit category, it cannot be excluded from coverage, either by statute or policy, and it must be medically necessary. Section 1862(a)(1)(A) of the Social Security Act precludes program payment for services not deemed to be medically necessary. This section of the Act underpins all Medicare regulations. Any document issued by CMS or any of its contractors, which contains statements regarding criteria for coverage and payment of any service (office visits, procedures, diagnostic tests, etc.) has as an underlying assumption that the service must comply with the requirements of §1862(a)(1)(A). The law states that the test cannot be reimbursed if it is not medically reasonable and necessary. As a consequence, it is incumbent upon the providers to be sure the service they provide is medically necessary, even in the instance where the documentation that proves medical necessity is created and/or housed by an entity other than the performing provider.

It is also important to recognize that medical necessity is not met simply by merely matching a procedure code to a diagnosis code, as may be listed in a policy. In the case of a diagnostic test, it may be medically necessary in some instances but not in others; or it may be medically necessary at some point in the treatment of the beneficiary but not at others. Otherwise stated, it is not enough to only link a procedure code to a correct, payable diagnosis code – the test must be appropriate and medically necessary at the time and point at which it is being performed in the course of the patient’s evaluation. Furthermore, the Code of Federal Regulations (CFR), Title 42, part 410.32, specifies that all diagnostic tests must be ordered by a provider who is the treating provider for the patient and who will use the test results in the patient’s care. Tests not ordered by the physician who is treating the beneficiary are not reasonable and necessary.

Like with any service reimbursed, to support medical necessity there must be documentation in the medical record as to why a certain modality was chosen/Performed. This entire documentation – not just the test report or the finding/diagnosis on the order – must be available for review in order to establish medical reasonableness and necessity criteria.

The EKG strip and a copy of the test results should be maintained in the medical record. In addition, the medical record must support that the physician interpreted and agrees with the test results and show that the results are being used to manage the patient.

If the provider of the service is other than the ordering/referring physician, that provider must maintain hard copy documentation of test results and interpretation, along with copies of the ordering/referring physician’s order for the studies. The physician must state the clinical indication/medical necessity for the study in the order for the test.

**Utilization Guidelines**

It is expected that these services would be performed as indicated by current medical literature and/or standards of practice. When services are performed in excess of established parameters, they may be subject to review for medical necessity.

**Sources of Information and Basis for Decision**

First Coast Service Options, Inc. reference LCD number(s) – L28866, L29163, L29337


**Start Date of Comment Period**

N/A

**End Date of Comment Period**
Electrocardiography.2 A/B

N/A

**Start Date of Notice Period**

N/A

**Revision History**

**Revision History Number: R2**

**Revision Number: 2**
Publication: September 2017 Connection
LCR A/B2017-038

Explanation of Revision: Based on CR 10153 (Annual 2018 ICD-10-CM Update) the LCD was revised. Changed diagnosis code range E85.1-E85.8 to E85.1-E85.89. Added ICD-10-CM diagnosis codes , P29.30 – P29.38. Deleted ICD-10-CM diagnosis codes E85.8, P29.3. The effective date of this revision is based on date of service.

**Revision History Number: R1**

Revision Number: 1
Publication: October 2016 Connection
LCR A/B2016-097

Explanation of Revision: Based on CR 9677 (Annual 2017 ICD-10-CM Update) the LCD was revised. Added ICD-10-CM diagnosis code ranges I16.0 – I16.9 and T88.53XA – T88.53XS. The effective date of this revision is based on date of service.

**Revision Number: Original**

This LCD replaces all previous LCD versions (refer to “Sources of Information and Basis for Decision” section of the LCD) and publications on this subject to comply with ICD-10-CM based on Change Request 8112. The effective date of this LCD is based on date of service.

**Related Documents**

N/A

**LCD Attachments**

Coding Guidelines

Document formatted: 09/06/2017 (RC/AC/dc)